MDK-701

MDK-701 is an investigational **IL-7 receptor agonist biologic** being developed by Medikine for immunology and oncology applications, including lymphopenia and cancer immunotherapy. The molecule is an **Fc-peptide fusion protein** composed of the synthetic peptide **MDK1319** fused to an Fc domain to extend pharmacokinetics. MDK1319 is structurally unrelated to native interleukin-7 but is designed to mimic IL-7 biology by engaging the **interleukin-7 receptor alpha** and **common gamma chain** receptor subunits, thereby promoting IL-7R signaling and lymphocyte expansion or maintenance. Based on the provided information, MDK-701 has shown preclinical activity in cynomolgus macaques, including a half-life of about 32 hours and peripheral lymphocyte effects similar to IL-7, with the non-native peptide design intended to reduce anti-drug antibody risk relative to IL-7 based therapeutics.

Other names

MDK1319 Fc fusion proteinMDK-1319 Fc fusion proteinMDK 1319 Fc fusion protein